# Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer

> **NCT01537536** · PHASE2 · COMPLETED · sponsor: **Jules Bordet Institute** · enrollment: 18 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** EndoTAG-1

## Key facts

- **NCT ID:** NCT01537536
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-09
- **Final completion:** 2012-11
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2013-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01537536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01537536, "Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01537536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*